Drugs / Panpulimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07419880 | Jan → Dec 2027 expected | triple-negative breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Panpulimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07419880 ↗ |
| Action | Inhibit | “Panpulimab: anti PD-1” NCT07419880 ↗ |